Phase II Study of Single Agent Sorafenib in the Treatment of Relapsed Esophageal/Gastric Adenocarcinoma in Platinum Pre-Treated Patients.
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 22 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 18 Jan 2014 Interim results presented at the 2014 Gastrointestinal Cancers Symposium.
- 09 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.